Estimate Recalculated Nov 8, 2024 09:33PM EST
Lindsay A MD Rosenwald has an estimated net worth of $74.6 Million. This is based on reported shares across multiple companies, which include ZIOPHARM ONCOLOGY INC, MANHATTAN PHARMACEUTICALS INC, NATIONAL HOLDINGS CORP, CB Pharma Acquisition Corp., Fortress Biotech, Inc., AVENUE THERAPEUTICS, INC., MUSTANG BIO, INC., Checkpoint Therapeutics, Inc., KERYX BIOPHARMACEUTICALS INC, Journey Medical Corp, GENTA INC DE/, INTRAC INC, Innovive Pharmaceuticals, Inc., Cougar Biotechnology, Inc., SITKA SCIENCES, INC., SEWARD SCIENCES, INC., NORTON SOUND ACQUISITION CORP., KODIAK SCIENCES, INC., KANAI SCIENCES, INC., DENALI SCIENCES, INC., CORDOVA SCIENCES, INC., CHITINA SCIENCES, INC., BRISTOL BAY SCIENCES, INC., ARCTIC ACQUISITION CORP., Paramount Acquisition Corp, NOVADEL PHARMA INC, CYPRESS BIOSCIENCE INC, and DOR BIOPHARMA INC.
Lindsay A MD Rosenwald's CIK is 0000941841
2005 was Lindsay A MD Rosenwald's most active year for acquiring shares with 82 total transactions. Lindsay A MD Rosenwald's most active month to acquire stocks was the month of December. 2006 was Lindsay A MD Rosenwald's most active year for disposing of shares, totalling 4 transactions. Lindsay A MD Rosenwald's most active month to dispose stocks was the month of May. 2023 saw Lindsay A MD Rosenwald paying a total of $5,378,051.02 for 7,442,937 shares, this is the most they've acquired in one year. In 2009 Lindsay A MD Rosenwald cashed out on 265,538 shares for a total of $9,594,245.33, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!